Gilead Sciences Inc.

25 jun 2026, 23:56 UTC

Gilead Sciences shares moved higher in after-market hours, despite earlier declines during regular trading amid mixed U.S. market performance influenced by economic data.

24 jun 2026, 23:36 UTC

Gilead Sciences' Trodelvy receives FDA approval for first-line treatment of triple-negative breast cancer, boosting shares in after-market hours.

23 jun 2026, 23:56 UTC

European Commission approves Gilead's Trodelvy for triple-negative breast cancer, boosting shares higher in after-market hours amid notable intraday fluctuations.

22 jun 2026, 23:02 UTC

Gilead Sciences Inc shares are lower in after-market hours, reversing earlier gains and settling near the lower end of their one-month trading range.

18 jun 2026, 23:06 UTC

Gilead Sciences shares are lower in after-market trading, reflecting a decline since Thursday's close and nearing the lower end of their one-month range.

17 jun 2026, 23:16 UTC

Gilead Sciences Inc. shares are lower in after-market hours, with notable volatility earlier in the session. No specific news was identified to explain the decline.

16 jun 2026, 23:36 UTC

Gilead Sciences Inc. shares gained slightly in after-market trading, fluctuating within a narrow range amid limited volatility and no specific company news.

15 jun 2026, 21:11 UTC

Gilead Sciences' supplemental New Drug Application for Yeztugo accepted by the FDA. Shares are lower in after-market trading despite the regulatory milestone.

12 jun 2026, 23:01 UTC

Gilead Sciences Inc. shares are higher in after-market trading, gaining slightly since Friday's close despite mixed broader market sentiment.

11 jun 2026, 23:02 UTC

Gilead Sciences reported positive results from two Phase 3 trials for an HIV treatment. Shares are higher in after-market hours following a session pullback.

10 jun 2026, 23:11 UTC

Gilead Sciences shares rose in after-market trading, driven by a strong Biotechnology sub-sector trend. The stock remains below its 20-day moving average.

9 jun 2026, 23:21 UTC

Gilead Sciences Inc shares are higher in after-market trading, rebounding from earlier losses despite remaining below the 20-day moving average.

8 jun 2026, 23:26 UTC

Gilead Sciences Inc. shares declined in after-market trading following the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study for Trodelvy and Keytruda.

5 jun 2026, 23:46 UTC

Gilead Sciences shares declined in after-market trading amid broader market pressures from strong U.S. job growth raising interest rate concerns.

4 jun 2026, 19:46 UTC

Gilead Sciences is gaining amid social media discussions on its strategic positioning and attention at Goldman Sachs' healthcare conference.

3 jun 2026, 23:01 UTC

Gilead Sciences Inc. is higher in after-market trading, driven by gains in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

2 jun 2026, 23:02 UTC

Gilead Sciences reported positive Phase 3 study results for Livdelzi® in treating primary biliary cholangitis. Shares are trading higher in after-market hours.

1 jun 2026, 20:03 UTC

Gilead Sciences Inc. shares are lower amid broader market concerns, despite plans to present over 25 abstracts at the ASCO Annual Meeting and EHA Congress.

29 may 2026, 20:02 UTC

Gilead Sciences is declining during Friday's session, despite the World Health Organization considering it for Ebola therapies. Shares rebounded earlier but fell back.

28 may 2026, 23:02 UTC

Gilead Sciences Inc shares are lower in after-market hours, reflecting broader market weakness amid disappointing jobless claims and inflation data.

27 may 2026, 23:02 UTC

Gilead Sciences shares are higher in after-market hours, recovering from earlier losses. The move comes amid broader market concerns about inflation and monetary policy.

26 may 2026, 20:02 UTC

Gilead Sciences shares are lower today despite a positive EMA opinion for Trodelvy® as a treatment for triple-negative breast cancer.

22 may 2026, 20:02 UTC

Gilead Sciences shares rise following FDA's accelerated approval of Hepcludex for chronic hepatitis delta virus, addressing a critical medical need.

21 may 2026, 20:06 UTC

Gilead Sciences renewed a five-year partnership with WHO to combat visceral leishmaniasis and acquired Tubulis GmbH for $3.15 billion. Shares are trading roughly flat.

20 may 2026, 23:46 UTC

Gilead Sciences has issued $3 billion in senior notes for general corporate purposes. Shares are trading lower during after-market hours amid ongoing pressure.

19 may 2026, 23:01 UTC

Gilead Sciences Inc shares are lower in after-market trading, despite positive economic data. The stock is near the lower end of its one-month trading range.

18 may 2026, 23:56 UTC

Gilead Sciences shares are modestly higher in after-market trading, recovering from earlier dips despite being below the 20-day moving average.

15 may 2026, 22:21 UTC

Gilead Sciences shares are lower in after-market hours, continuing a trend of declining daily closes and remaining below the 20-day moving average.

14 may 2026, 23:01 UTC

Gilead Sciences shares are higher in after-market hours, reflecting price action amid mixed labor market data and upcoming Federal Reserve meetings.